Category Archives: Business and Investments

Latest From Business and Investments

BIO CEO 2012 Opening Remarks

The 14th Annual BIO CEO & Investor Conference started with a busy turnout Monday at the Waldorf=Astoria Hotel in New York City. Meetings scheduled between institutional investors and biotech executives hit a record high and the opening plenary was a standing room only event. Kicking off the plenary were opening remarks from BIO’s Executive Vice President of Emerging Companies and Business Development, Alan Eisenberg. A copy of the slides can be found here: Opening Plenary Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

A Very Big BTK January

BTK-Jan-1992-2012-115x76

We all heard reports that January was a great start to 2012 for the stock market, and even more so for Biotech. But how big was it, really? The Amex Biotech Index (the “BTK“) had its biggest January on record, since 1992, with a +21% pop: The companies behind the numbers? The Nasdaq Biotech Index was up 11%, the best in a decade. The January 2000 jump of 15% is still a tough month to beat Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO CEO Company Snapshot: ImmunoGen, Inc.

immunogen-thumb

In the latest Company Snapshot for the 2012 BIO CEO & Investor Conference in New York City, we’re profiling ImmunoGen, Inc. which will be presenting at the event. We spoke with ImmunoGen, Inc. CEO Daniel Junius and he outlined his organization’s priorities and challenges as well as how his company differentiates themselves from the competition. Company Snapshot What are the short-term and long-term priorities for your company? Our highest priority today is building and advancing our pipeline Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Managing in a Cost-Constrained Environment

medicine-thumb

By Jill E. Sackman, D.V.M., Ph.D., Senior Consultant, and Matt Levy, J.D., Business Analyst, at Numerof & Associates, Inc. (NAI) The pharmaceutical industry has entered a critical period of transition. Business models that have proven remarkably successful over the past 20 years are now encountering major challenges. As biotech companies grapple with the leading symptoms of these challenges – pricing pressures, pipeline productivity concerns, a growing public distrust, and greater political and regulatory scrutiny – Read More >

Business of Biotech  |  1 Comment  |  Email This Post
Tags: , , , , ,

Virginia is for (Science) Lovers

Pam Moran

In Albemarle County, Virginia, the public school division is debuting a Health and Medical Sciences Academy this fall. Public high school students throughout the county will apply for a four-year program with a curricular concentration on skill sets that will serve state and national needs in the healthcare, pharmaceutical and research industries. In the following guest blog post, Dr. Pamela R. Moran, Superintendent of Albemarle County Public Schools, discusses this innovative program and offers insight Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: ,